MAIA Biotechnology, Inc.
AMEX:MAIABiotechnology
+$0.05 today
- Market cap
- $80.28M
- Beta
- 0.24
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.76
Volume 2.25M
Average 0.78M
MAIA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
MAIA Biotechnology, Inc.AMEX: MAIA
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $3.42M rose 53.7% year over year, ahead of the +44.7% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 40.6% from the prior quarter. Over 3 fiscal years it compounded at +1065.3% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 1 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +139830.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $3.42M+40.6% QoQ
- Last fiscal yearDec 2025
- $9.72B+139830.6% YoY
- LTMMar 2026
- $10.92M+44.7% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 9.72B USD
- Year-over-year change
- +139830.6%
- 4-year CAGR
- +590.0%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.72B | +139830.6% |
| FY2024 | 2024-12-31 | 6.95M | -23.4% |
| FY2023 | 2023-12-31 | 9.07M | +47.6% |
| FY2022 | 2022-12-31 | 6.14M | +43.2% |
| FY2021 | 2021-12-31 | 4.29M | — |
Selling, General & Admin vs competitors
How MAIA compares with its peers on the latest reported figures
- MAIA's LTM Mar 2026 selling, general & admin of $10.92M is the 4th highest of the 7 companies compared; the peer median is $13.67M.
- Its year-over-year change of +44.7% is the 4th highest of 7, against a peer median of +31.4%.
- Over three fiscal years its annual growth of +1065.3% compares with a peer median of -6.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.3B | +19278.2% | -20.7% | — | |
| LTM Dec 2025 | $51.27M | -12.6% | -8.1% | 193.1% | |
| LTM Mar 2026 | $17.65M | -31.3% | -22.7% | — | |
| LTM Mar 2026 | $10.92M | +44.7% | +1065.3% | — | |
| LTM Mar 2026 | $9.7M | +78.7% | -5.6% | — | |
| LTM Mar 2026 | $8.2M | +53.6% | +7.6% | 550.8% | |
| LTM Mar 2026 | $6.63M | +9.3% | +3.5% | — | |
| Peer median (excluding MAIA) | $13.67M | +31.4% | -6.9% | 372.0% | |
Competitors are the stored peer set for MAIA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 3.45M | 8.93M | 11.11M | 10.01M | 14.55B |
| Selling, General & Admin | 4.29M | 6.14M | 9.07M | 6.95M | 9.72B |
| Operating Expenses | 7.79M | 16.18M | 20.18M | 16.96M | 24.27M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | (11.75M) | (15.76M) | (19.77M) | (23.25M) | (22.4M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (7.79M) | (16.18M) | (20.18M) | (16.96M) | (24.27M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 2.01K | 1.87K | 27.63K | 318.37K | 313.95K |
| Interest Expense | 827.54K | 6.97K | 0 | 57 | 0 |
| Other Income / Expenses | (4.79M) | 406.92K | 409.48K | (6.3M) | 1.87M |
| Income Before Tax | (12.58M) | (15.77M) | (19.77M) | (23.25M) | (22.4M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (12.5M) | (15.77M) | (19.77M) | (23.25M) | (22.4M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.18) | (1.70) | (1.49) | (1.05) | (0.70) |
| EPS (Diluted) | (1.18) | (1.70) | (1.49) | (1.05) | (0.70) |
| Weighted Avg Shares | 10.64M | 9.28M | 13.26M | 22.2M | 32.12M |
| Weighted Avg Shares (Diluted) | 10.64M | 9.28M | 13.26M | 22.2M | 32.12M |
MAIA Biotechnology, Inc.
AMEX:MAIA
Intrinsic Alpha fair value
Locked
Current Price
$1.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.